PTPN2 and chronic myelogenous leukemia, BCR-ABL1 positive: Taken together, PtPT may have clinical efficacy against human CML driven by activated Bcr-Abl regardless of the mutation status, providing great importance in future clinical CML therapy, particularly in those suffering from imatinib resistance.